"Hey, this changes everything": EpiSwitch PSE on Health Uncensored with Dr. Drew

Last updated: 01 Jun 2026

"Every once in a while, a breakthrough shows up that causes physicians to stop and say, 'Hey, this changes everything.' Today, we're looking at a new molecular blood test built to bring clarity to prostate cancer care using a simple blood draw."

That was how Dr. Drew opened his Sunday 17 May segment of Health Uncensored with Dr. Drew on Fox Business, talking about the EpiSwitch® PSE prostate cancer detection test. Joining the show was board-certified urologist Garrett Pohlman, MD, of Kearney Urology Center, a regular user of PSE in his clinical practice. Over five compelling minutes, the two physicians walked viewers through exactly why PSA alone is not enough, and what PSE is changing on the ground.

The problem with PSA: A good 'check engine light', but not the full picture

Dr. Drew set the scene with a candour that will resonate with any man who has sat in a urologist's waiting room: "One number, high stakes, and a lot of uncertainty. That's how prostate cancer screening often begins." He described how a single PSA result "can send a man down a stressful path: scans, procedures, hard conversations, sometimes without clear answers along the way."

Dr. Drew knows this first-hand. He shared with viewers that his own PSA had climbed from 1 to 4 ng/ml, still technically within normal range, but his doctor flagged the rate of change as significant. After antibiotics and anti-inflammatories failed to bring it down, a biopsy was next.

Dr. Pohlman put it plainly: PSA is "a great check engine light for men in their prostate, but it doesn't tell us exactly what's going on." Inflammation, infection — and yes, prostate cancer — can all drive PSA upward. The problem, he explained, is the lack of specificity with PSA, which can lead to unnecessary biopsies. 3 in 4 men with a raised PSA go on to have a negative prostate biopsy.

Enter EpiSwitch PSE: Clarity before the biopsy

The PSE test analyses a fingerprint in the blood, seen time and time again in men with prostate cancer: five epigenetic markers developed by Oxford BioDynamics, in combination with PSA. Dr. Pohlman described it as the tool that belongs in the workflow before jumping into a biopsy.

The PSE delivers a clear binary result with 94% accuracy: either a Low Likelihood or a High Likelihood of prostate cancer. That result, he explained, gives patients "that confidence to proceed on with the next step, whether that be continued observation, repeating another PSA in 6 to 12 months or proceeding on with more testing including the MRI, the biopsy."

Critically, Dr. Pohlman stressed that no PSA rise should be written off. He has detected clinically significant prostate cancer in patients with only a marginally elevated PSA. The PSE is a tool that allows clinicians to determine precisely how seriously to take that rise, without automatically sending patients down an invasive diagnostic pathway and the anxiety this can bring.

94% accuracy and real-world evidence of up to 79% of biopsies avoided

Dr. Pohlman brought numbers to the conversation from a real-world study from his clinic, Kearney Urology Center, involving 187 men with elevated PSA or an abnormal digital rectal exam. When used in the pre-biopsy workflow, he explained, "we were able to avoid unnecessary biopsies in up to 79% of men" all without missing any high-grade disease.

Dr. Drew, who has spent decades demystifying medicine for general audiences, immediately grasped the significance: "Each patient is very different. Each tumor is very different in prostate cancer. In making those therapeutic decisions, we need lots of information." PSE is designed to provide exactly that: more information, earlier, from a simple blood draw.

The patient response was equally telling. Every eligible man in the real-world study chose PSE when it was offered, underscoring a strong patient appetite for clarity before considering invasive procedures.

Dr. Drew closed the segment plainly: "I'm so glad this is a new way of screening, or increasing the probability that a biopsy is necessary." By unlocking 3D genomic biomarkers, EpiSwitch PSE is already helping transform a historically ambiguous part of the diagnostic pathway into a more precise, patient-centred process. It is helping to bring real clarity to men, their families, and their physicians.

Watch Dr. Pohlman's full segment on Health Uncensored with Dr. Drew above. If you or someone you care about is navigating a rising PSA or has a family history of prostate cancer, this is worth your time.

To learn more about EpiSwitch PSE: Oxford BioDynamics: PSE.

To learn more prostate health tips, tune in for weekly episodes of The Prostate Health Podcast where Dr. Garrett Pohlman interviews his fellow Urologists: The Prostate Health Podcast